Publication Name	World Journal of Gastroenterology
Manuscript ID	88715
Country	China

Received	2023-10-07 02:23
Peer-Review Started	2023-10-07 02:26
To Make the First Decision
Return for Revision	2023-10-23 03:44
Revised	2023-11-08 14:52
Second Decision	2023-11-28 10:44
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2023-12-06 05:40
Articles in Press	2023-12-06 05:40
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2023-12-22 05:35
Publish the Manuscript Online	2023-12-27 05:42

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Letter to the Editor
Article Title	Potential therapeutic targets for nonalcoholic fatty liver disease: Glucagon-like peptide 1
Manuscript Source	Unsolicited Manuscript
All Author List	Yue-Hua Yin, Li-Xuan Sang and Bing Chang
ORCID	Author(s) ORCID Number Yue-Hua Yin http://orcid.org/0009-0002-8560-9984 Li-Xuan Sang http://orcid.org/0000-0002-4562-0022 Bing Chang http://orcid.org/0000-0003-1965-5827
Funding Agency and Grant Number
Corresponding Author	Bing Chang, N/A, Chief Physician, Postdoc, Professor, Department of Gastroenterology, The First Affiliated Hospital of China Medical University, No. 155 Nanjing North Street, Shenyang 110001, Liaoning Province, China. cb000216@163.com
Key Words	Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Antidiabetic drugs; Glucagon-like peptide 1; Semaglutide
Core Tip	Semaglutide is effective and safe for nonalcoholic fatty liver disease (NAFLD) but does not improve fibrosis. The treatment of NAFLD requires further combinations of drugs with different and complementary mechanisms of action.
Publish Date	2023-12-27 05:42
Citation	Yin YH, Sang LX, Chang B. Potential therapeutic targets for nonalcoholic fatty liver disease: Glucagon-like peptide 1. World J Gastroenterol 2023; 29(48): 6235-6238
URL	https://www.wjgnet.com/1007-9327/full/v29/i48/6235.htm
DOI	https://dx.doi.org/10.3748/wjg.v29.i48.6235

Full Article (PDF)	WJG-29-6235-with-cover.pdf
Full Article (Word)	WJG-29-6235.docx
Manuscript File	88715_Auto_Edited-JLW.docx
Answering Reviewers	88715-Answering reviewers.pdf
Audio Core Tip	88715-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	88715-Conflict-of-interest statement.pdf
Copyright License Agreement	88715-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	88715-Language certificate.pdf
Peer-review Report	88715-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	88715-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	88715-Bing-Qu XL-2.jpg
Scientific Editor Work List	88715-Scientific editor work list.pdf